Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5277970
Max Phase: Preclinical
Molecular Formula: C97H184N22O22
Molecular Weight: 2010.67
Associated Items:
ID: ALA5277970
Max Phase: Preclinical
Molecular Formula: C97H184N22O22
Molecular Weight: 2010.67
Associated Items:
Canonical SMILES: CCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C(N)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC
Standard InChI: InChI=1S/C97H184N22O22/c1-16-24-25-26-27-46-71(121)105-53-72(122)113-73(56(9)17-2)94(137)117-75(58(11)19-4)90(133)109-63(40-28-34-47-98)85(128)107-67(44-32-38-51-102)88(131)115-78(61(14)22-7)96(139)119-77(60(13)21-6)92(135)111-65(42-30-36-49-100)86(129)108-68(45-33-39-52-103)89(132)116-79(62(15)23-8)95(138)118-76(59(12)20-5)91(134)110-64(41-29-35-48-99)84(127)106-66(43-31-37-50-101)87(130)114-74(57(10)18-3)93(136)112-69(83(104)126)55-140-97-82(125)81(124)80(123)70(54-120)141-97/h56-70,73-82,97,120,123-125H,16-55,98-103H2,1-15H3,(H2,104,126)(H,105,121)(H,106,127)(H,107,128)(H,108,129)(H,109,133)(H,110,134)(H,111,135)(H,112,136)(H,113,122)(H,114,130)(H,115,131)(H,116,132)(H,117,137)(H,118,138)(H,119,139)/t56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70+,73-,74-,75-,76-,77-,78-,79-,80-,81-,82+,97+/m0/s1
Standard InChI Key: YFZGRZMMFAWIOK-ZQYLTBJOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2010.67 | Molecular Weight (Monoisotopic): 2009.3956 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Cao R, Li L, Xu Z, Li J, Wu D, Wang Y, Zhu H.. (2023) The lipidation and glycosylation enabling bioactivity enhancement and structural change of antibacterial peptide G3., 90 [PMID:37182609] [10.1016/j.bmcl.2023.129322] |
Source(1):